Introduction L-Dopa produces improvement in the manifestations of Parkinsonism and has an important therapeutic role in this common condition (Cotzias et al, 1968 (Cotzias et al, , 1969 Yahr et al., 1968 Yahr et al., , 1969 Calne et al., 1969a Calne et al., , 1969b Godwin-Austen et al., 1969b) . Both hypertension and, more commonly, hypotension may occur during L-dopa therapy (Cotzias et al., 1968 (Cotzias et al., , 1969 Yahr et al., 1968 Yahr et al., , 1969 . The most likely explanation of these observations is that L-dopa therapy interferes with sympathetic activity, which in turn leads to hypotension, particularly in the erect posture.
We have investigated the pupillary aperture in patients during and after L-dopa therapy as a convenient measure of peripheral sympathetic activity.
Patients and Methods
Eleven patients participating in a trial of L-dopa therapy in idiopathic Parkinsonism (Calne et al., 1969b) were studied. Their ages ranged from 47 to 65 years and their initial Parkinsonian symptoms varied from mild to gross disability. The daily doses of L-dopa ranged from 1.0 to 6.8 g. (mean 3.2 g.). For each patient an ocular photograph was taken during maintenance with maximum tolerated doses of L-dopa. Photographs were taken at 12.30 p.m., four hours after the most recent dose of L-dopa. The second series of photographs was made several weeks after ceasing L-dopa therapy.
To ensure constant lighting and to minimize the effects of tremor the head rest and lighting system of a Leitz slit-lamp were used. Measured light intensities were reproduced between series of photographs. Photographs were taken with an Exakta Varex IIB 35-mm. camera, a Trioplan 10-cm. lens with focusing bellows and Ilford HP4 film being used. The back of the camera was 40 cm. from the bridge of the subject's nose. To avoid the effects of accommodation, patients looked "through" the camera lens without focusing. Three photographs were made on each occasion and negatives were projected on to the wall of a darkroom, giving a final magnification of x 15. Measurements of the horizontal diameter of the pupil were made. Observations were performed on the left eye: all three photographs in each patient were used and the mean of the readings was taken.
Results
Variations in pupillary diameter within each set of three photographs were small (often less than 1 mm. on the magnified image), suggesting that fluctuations in accommodation were not affecting results.
Pupillary diameters during and after L-dopa therapy, and the percentage differences for each patient, are set out in the Table. In 10 of the 11 patients the pupil was smaller during L-dopa therapy than after its cessation. A Wilcoxon signed rank test showed that the difference in pupillary diameters is significant at the 0.1% level.
The extent of miosis in individual patients showed no correlation with the dose of L-dopa, the development of hypotension, or the response of the Parkinsonism to therapy. There was a similar lack of correlation between dose, hypotension, and therapeutic response. 
Discussion
The finding of a significant miosis during L-dopa therapy is compatible with the hypothesis that sympathetic tone is reduced by this treatment. The demonstration of orthostatic hypotension during L-dopa therapy also accords well with this view. Reduced sympathetic activity during therapy with a drug which is a precursor of noradrenaline may appear paradoxical. It has been shown, however, that both d-opamine (Spiers and Calne, 1969) and L-dopa cause release of noradrenaline from sympathetic nerve endings, and may produce depletion of noradrenaline stores, even though both drugs are precursors of noradrenaline. That amine release by dopamine may outstrip synthesis has been shown in animal experiments (Harrison et al., 1963; Eranko and Raisanen, 1968) . Administration of L-dopa restores the noradrenaline content of peripheral adrenergic nerves after reduction by reserpine (Pennefather and Rand, 1960) , but apparently does not increase peripheral noradrenaline stores when these are initially normal. Though treatment with Ldopa increases the dopamine oontent of rabbit brain, changes in noradrenaline levels are slight or absent (Carlsson et al., 1958) .
During long-term therapy with L-dopa by mcuth pupillary dilatation has sometimes been observed one to two hours after an oral dose of L-dopa (van Woert, personal commu-MEDICAL JIURNAL nication, 1969). Many of our patients report an awakening reaction shortly after taking L-dopa, with symptoms resembling those following ingestion of amphetamine. These observations are compatible with the view that L-dopa causes release of amines from adrenergic nerve endings. The significant miosis we have observed with continuous oral Ldopa therapy, like the hypotension, may reflect decreased peripheral sympathetic activity following noradrenaline depletion at sympathetic nerve endings. Since the drug causing depletion is itself a noradrenaline precursor such depletion might be only partial. This expectation is confirmed by the finding (Godwin-Austen et al., 1969a ) that patients treated with L-dopa still show a mydriatic response to tyramine, which acts by releasing noradrenaline from nerve endings in the iris.
Diminished mydriasis with phenylephrine reported during L-dopa therapy has been attributed to a -adrenergic receptor blockade by L-dopa or its metabolites (GodwinAusten et al., 1969a) . A brisk mydriatic response to phenylephrine drops, howevej, still occurs in eyes treated with high concentrations of dopamine or L-dopa for several hours (Spiers and Calne, 1969; . Since prolonged application of high ooncentrations of a drug is a sensitive test for blocking activity, it seems unlikely that dopamine or L-dopa produces significant a-blockade.
Miosis is not always detectable during L-dopa therapy; no change in resting pupillary size was detected in one series of 18 patients (Godwin-Austen et al., 1969a) . Absence of miosis in these patients might be due to short duration of L-dopa therapy (Spiers, 1969) or to the timing of ocular photography. If this was done shortly after a dose of L-dopa the acute mydriatic effects of the drug, due to amine release, would mask the underlying chronic miosis, due to partial amine depletion. Timing of observations may well explain the occasional observation of hypertension instead of hypotension during L-dopa therapy, for intravenous administration of Ldopa to man produces an acute hypertensive response (Degkwitz, et al., 1960) which accords well with its acute mydriatic effects.
The effect of L-dopa and dopamine on adrenergic nerve endings may be more complex than simple noradrenaline depletion. Collins and West (1968) showed that incubation of rabbit ileum with dopamine or L-dopa leads to accumulation of dopamine within the sympathetic nerve terminals, and subsequent stimulation of the nerves releases dopamine. Burn (personal communication, 1969) , suggested that in patients receiving L-dopa nerve impulses may release a normal amount of total catecholamines, but much of this will be dopamine, so the quantity of noradrenaline released by each impulse will be subnormal. Since dopamine has less capacity than noradrenaline to stimulate a -adrenergic receptors (Goldberg et al., 1969) , the effects of sympathetic nerve impulses will be diluted. Under these circumstances hypotension, miosis, and perhaps a reduced cardiac response to exercise are possible clinical results of L-dopa therapy.
An alternative explanation of all these observations is that L-dopa exerts its sympatholytic action centrally, possibly by modulating levels of brain amines.
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